NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Technology Appraisal (Committee D) meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 13 January 2021

**Location:** Via Zoom

# Committee members present:

1. Professor Gary McVeigh [Chair Topic 1] Present for all items
2. Professor Steve O’Brien [Chair Topic 2] Present for items 4 to 4.4.2
3. Dr Lindsay Smith [Vice Chair] Present for all items
4. Dr Matt Bradley Present for all items
5. Professor Sofia Dias Present for items 4 to 4.4.2
6. Professor Rachel Elliott Present for all items
7. Professor Paula Ghaneh Present for all items
8. Dr Rebecca Harmston Present for all items
9. Dr Robert Hodgson Present for all items
10. Dr Bernard Khoo Present for items 1 to 3.3
11. Dr Soo Fon Lim Present for all items
12. Dr Guy Makin Present for all items
13. Professor David Meads Present for all items
14. Giles Monnickendam Present for all items
15. Malcolm Oswald Present for all items
16. Baljit Singh Present for all items
17. Dr John Watkins Present for all items

# NICE staff present:

Linda Landells, Associate Director Present for items 1 to 3.4.2

Ross Dent, Associate Director Present for items 4 to 4.4.2

Kate Moore, Project Manager Present for items 1 to 3.4.2

Louise Jafferally, Project Manager Present for items 4 to 4.4.2

Caron Jones, Technical Adviser Present for items 1 to 3.4.2

Sally Doss, Technical Adviser Present for items 4 to 4.4.2

Amy Crossley, Technical Analyst Present for 1 to 3.4.2

Fatima Chunara, Technical Analyst Present for items 4 to 4.4.2

Heidi Livingstone, Public Involvement Adviser Present for items 1 to 3.3

Laura Marsden, Public Involvement Adviser Present for items 4 to 4.3

Sandra Robinson, Coordinator, MIP Present for items 1 to 3.3 & 4 to 4.3

Mira Patel, Coordinator, COT Present for all items 1 to 3.3 & 4 to 4.4.2

Gemma Smith, Coordinator, COT Present for all items

Celia Meyers, Administrator, TA Present for items 1 to 3.4.2

Pratit Shah, Administrator, TA Present for items 4 to 4.4.2

# External group representatives present:

Lindsay Claxton, Centre for Reviews and Dissemination and Centre for Health Economics - York, Present for items 1 to 3.3

Mark Corbett, Centre for Reviews and Dissemination and Centre for Health Economics -York, Present for items 1 to 3.3

Sabine Grimm, Kleijnen Reviews Ltd Present for items 4 to 4.3

Robert Wolff, Kleijnen Reviews Ltd Present for items 4 to 4.3

# Professional experts present:

Dr Emma Drasar, Consultant Haematologist, University College Hospital NHS Trust

Whittington Hospital NHS Trust, Present for items 1 to 3.3

Sharon Hodgson, Commissioning expert, NHS England, Present for items 1 to 3.3

Roanna Maharaj, Public Health, Projects and Patient Advocacy Lead, UK Thalassaemia Society, Present for items 1 to 3.3

Dr Kate Ryan, Consultant Haematologist, Manchester Royal Infirmary, Present for items 1 to 3.3

Gabriel Theophanous, Chair, UK Thalassaemia Society, Present for items 1 to 3.3

Peter Clark, CDF Clinical Lead, NHS England, Present for items 4 to 4.3

Dr Eve Gallop-Evans, Consultant Clinical Oncologist & Clinical Director, Velindre University NHS Trust, Present for items 4 to 4.3

Professor Julia Scarisbrick, Consultant Dermatologist & Lead Cutaneous Lymphoma Service, University Hospitals Birmingham NHS Foundation Trust, Present for items 4 to 4.3

Stephen Scowcroft, Director of Operations and External Affairs, Lymphoma Action, Present for items 4 to 4.3

# NICE Observers present:

Helen Barnett, Medical Editor Present for items 1 to 3.4.2

Ann Greenwood, Medical Editor Present for items 4 to 4.4.2

Thomas Lawrence, Data Scientist, Managed access Present for items 1 to 3.4.2

Ella Livingstone, Technical Adviser, Commercial risk assessment Present for items 1 to 3.4.2

Charlotte Pelekanou, HTA Analyst, MTEP, Present for items 1 to 3.4.2

Maroulla Whiteley, Business Analyst, RIA Present for all items

1. Introduction to the meeting
   1. The chair welcomed members of the committee and other attendees present to the meeting.
2. News and announcements
   1. None.
3. Appraisal of Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]
   1. Part 1 – Open session
      1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Bluebird Bio.
      2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Giles Monnickendam declared a financial interest as his employer [Vitaccess] has conducted a digital registry study on burden of disease in transfusion dependent beta-thalassaemia for Bluebird Bio.
* It was agreed that his declaration would not prevent Giles from participating in this section of the meeting.
* No further conflicts were declared for this appraisal.
  1. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
  2. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
  3. Part 2 – Closed session [company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting]
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD]. The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD] in line with their decisions.

1. Appraisal of Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome [ID1405]
   1. Part 1 – Open session
      1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Kyowa Kirin.
      2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Professor David Meads declared non-financial interest as the University of Leeds has received funding from Takeda for research in an unrelated area.
* It was agreed that his declaration would not prevent David from participating in this section of the meeting.
* Dr Matt Bradley declared a non-financial interest as GSK, is in a co-marketing agreement with Kyowa Kirin for medicine in an unrelated disease area that is only available in Japan.
* It was agreed that his declaration would not Matt from participating in this section of the meeting.
* Steven Scowcroft declared indirect interests as Lymphoma Action are supported by pharma organisations including the one involved with this HTA and that they have received funding from Roche and Takeda in unrelated areas.
* It was agreed that his declaration would not Steven from providing expert advice to the committee.
* Professor Julia Scarisbrick declared financial interests she is PI on MAVORIC trial and has previously received consultancy fees from Kyowa Kirin.
* It was agreed that her declaration would not Julia from providing expert advice to the committee.
* Dr Eve Gallop-Evans declared a financial interest as she has received honorarium from Kyowa Kirin for an advisory board meeting on 4 March 2019
* It was agreed that her declaration would not Eve from providing expert advice to the committee.
* No further conflicts of interest were declared for this item.
  1. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document [ACD] or Final Appraisal Document [FAD] received from consultees, commentators and through the NICE website.
  2. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
  3. Part 2 – Closed session [company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting].
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD]. The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD] in line with their decisions.

1. Date of the next meeting

The next meeting of the Technology Appraisal (Committee D) will be held on Thursday 11 February 2021 and will start promptly at 09.30am.